



Technivie® (ombitasvir/paritaprevir/ritonavir) – Expanded indication

- On February 27, 2017, the [FDA approved](#) AbbVie's [Technivie \(ombitasvir/paritaprevir/ritonavir\)](#), in combination with [ribavirin](#) for the treatment of patients with genotype 4 (GT4) chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis.
 - Previously, Technivie was approved only in patients without cirrhosis.
- Efficacy for the expanded indication of Technivie was based on the AGATE-I trial. This was an open-label study of 120 patients with GT4 chronic HCV infection with compensated cirrhosis treated with Technivie and ribavirin for 12 or 16 weeks. The primary endpoint was sustained virologic response 12 weeks after the end of treatment (SVR₁₂).
 - The SVR₁₂ was 97% (57/59) for patients treated for 12 weeks.
 - Treatment for 16 weeks was not shown to further increase SVR₁₂ rates.
- Technivie carries a boxed warning for risk of hepatitis B virus (HBV) reactivation in patients co-infected with HCV and HBV.
- The most common adverse events (> 10%) with Technivie and ribavirin use in patients with compensated cirrhosis were fatigue, asthenia, headache, musculoskeletal pain, pruritus, insomnia/sleep disorder, skin reactions, mood disorders, nausea, dizziness and dyspnea.
- For patients without cirrhosis or with compensated cirrhosis, the recommended dose of Technivie is two tablets orally once daily (in the morning) with a meal in combination with ribavirin for 12 weeks.
 - Technivie may be administered without ribavirin in treatment-naïve patients without cirrhosis who cannot take or tolerate ribavirin.
 - Technivie is contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh B and C).
 - Refer to the ribavirin prescribing information for specific dosing instructions.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.